Nick Fox - Selected Publications#

O'Connor A, Pannee J, Poole T, Arber C, Portelius E, Swift IJ, Heslegrave AJ, Abel E, Willumsen N, Rice H, Weston PSJ, Ryan NS, Polke JM, Nicholas JM, Mead S, Wray S, Chávez-Gutiérrez L, Frost C, Blennow K, Zetterberg H, Fox NC. (2021) . Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype. Brain. 144(10):2964-2970. doi: 10.1093/brain/awab166.

O'Connor A, Karikari TK, Poole T, Ashton NJ, Lantero Rodriguez J, … Fox NC. (2020). Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. Mol Psychiatry, doi: 10.1038/s41380-020-0838-x

- This paper was the first to show the value of this blood-based biomarker in detecting AD presymptomatically: p-tau-181 is now a key candidate marker in AD prevention studies.

Lane CA, Barnes J, Nicholas JM, Sudre CH, … Fox NC, Schott JM. (2019). Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. Lancet Neurol. (10):942-952.

- This highly cited paper shows the importance of midlife blood pressure for brain health decades later.

Weston PSJ, Nicholas JM, Henley SMD, Liang Y, Macpherson K, Donnachie E, Schott JM, Rossor MN, Crutch SJ, Butler CR, Zeman AZ, Fox NC. (2018). Accelerated long-term forgetting in presymptomatic tosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurol. 17(2):123-132. doi: 10.1016/S1474-4422(17)30434-9. -

This paper was the first to show that a novel appraoch to assessing memory function could detect presymptomatic cognitive decline in Alzheimer's disease.

Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, Larson EB, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N. (2017). Dementia prevention, intervention, and care. Lancet. Jul 19. pii: S0140-6736(17)31363-6. PMID: 28735855-

This report, commissioned by The Lancet, has had almost 1,000 citations per year.

Ryan NS, Nicholas JM, Weston PS, Liang Y, Lashley T, … Fox NC. (2016). Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series. Lancet Neurol. Dec;15(13):1326-1335.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, … Bapineuzumab 301 and 302 clinical trial investigators. (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. NEJM, 370:322-33.

Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M. (2005). Effects of Ab immunization (AN1792) on MRI measures of cerebral volume in Alzheimer’s disease. Neurology, 64:1563-72.-

This paper reports on the first and pivotal amyloid immunotherapy (vaccination) study in Alzheimer's disease. I led the MRI image analyses for the study using a technique I developed. The paper has been cited over 500 times.

Chan D, Janssen JC, Whitwell JL, Watt HC, Jenkins R, … Fox NC. (2003). Change in rates of cerebral atrophy over time in early-onset Alzheimer’s disease: longitudinal MRI study. Lancet 2003; 362:1121-1122.

Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. (2002). Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI. PNAS 2002; 99:4703-7.-

The technique of using registration of serial MRI (which I developed) has since been used in over 30 international clinical trials - with 10s of thousands of scans analysed - this paper showed the ability to localise brain atrophy presymptomartically.